BMRN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
989.7M
+29.2%
766.2M
-12.4%
874.6M
+12.7%
776.1M
-6.0%
825.4M
Cost of Revenue
202.8M
+4.0%
195.0M
-29.3%
275.7M
+96.8%
140.1M
-6.7%
150.1M
Gross Profit
786.9M
+37.8%
571.2M
-4.6%
598.9M
-5.8%
636.0M
-5.8%
675.3M
Operating Expenses
672.7M
+52.3%
441.6M
-31.4%
643.5M
-5.8%
682.7M
+73.5%
393.6M
R&D
207.0M
+15.7%
178.8M
-7.1%
192.4M
-53.0%
409.5M
+153.8%
161.3M
SG&A
395.5M
+53.1%
258.3M
-42.1%
446.2M
+66.2%
268.4M
+15.6%
232.3M
Operating Income
114.2M
-11.9%
129.6M
+390.6%
-44610000
+4.5%
-46692000
-116.6%
281.7M
EBITDA
211.8M
+45.0%
146.1M
+704.2%
-24172000
+14.3%
-28205000
-109.4%
300.3M
Net Income
44.8M
-57.6%
105.5M
+326.6%
-46573000
-51.5%
-30744000
-112.8%
240.5M
EPS (Basic)
$0.23
-58.2%
$0.55
+329.2%
$-0.24
-50.0%
$-0.16
-112.8%
$1.25
EPS (Diluted)
$0.23
-57.4%
$0.54
+334.8%
$-0.23
-43.8%
$-0.16
-113.0%
$1.23
Shares (Diluted)
194.5M
-1.6%
197.7M
-3.1%
204.0M
+6.2%
192.0M
-2.6%
197.1M
BioMarin Pharmaceuticals (BMRN) โ€” Financials